Oritavancin: A novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains

International Journal of Antimicrobial Agents

Volumn 36, Issue 5, 2010, Pages 401-407

  Bouza, Emilio ^a,b   Burillo, Almudena ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Glycopeptides; Gram positive bacterial infections; Oritavancin; Therapeutic use; Vancomycin resistance

Indexed keywords

CEFALEXIN; DAPTOMYCIN; GENTAMICIN; MACROGOL; ORITAVANCIN; PLACEBO; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BIOFILM; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CONCENTRATION RESPONSE; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTROL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; ENDOCARDITIS; ENTEROCOCCAL INFECTION; ERADICATION THERAPY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE BACTERIUM; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; KIDNEY INJURY; LIVER INJURY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NAUSEA; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PHENOTYPE; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RECOMMENDED DRUG DOSE; SHORT SURVEY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCAL PNEUMONIA; TEMPORAL ARTERITIS; THROMBOSIS; TREATMENT DURATION; VOMITING;

ANTI-BACTERIAL AGENTS; BIOFILMS; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; ENTEROCOCCUS; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 77957679579     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.06.048     Document Type: Short Survey

References (72)

1. Allen N.E., Nicas T.I. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003, 26:511-532.
2. Malabarba A., Ciabatti R., Kettenring J., Ferrari P., Scotti R., Goldstein B.P., et al. Amides of de-acetylglucosaminyl-deoxy teicoplanin active against highly glycopeptide-resistant enterococci. Synthesis and antibacterial activity. J Antibiot (Tokyo) 1994, 47:1493-1506.
3. Lehoux D., Okusanya O.O., Laquerre K., Forrest A., Ostiguy V., Bhavnani S.M., et al. PK-PD of oritavancin (ORI) against Streptococcus pneumoniae (SP) in a murine-pneumonia infection model. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 17-20 September 2007, Chicago, IL 2007, ASM Press, Washington, DC, [Abstract A-49].
4. Van Bambeke F., Virgincar N., MacGowan A. Glycopeptides (dalbavancin, oritavancin, teicoplanin, telavancin, vancomycin). Antimicrobial agents 2009, Antimicrob.org, Pittsburgh, PA, [accessed 5 February 2010]. http://www.antimicrobe.org/d14rev.asp, S.U. Burdette, V.L. Yu (Eds.).
5. Van Bambeke F., Van Laethem Y., Courvalin P., Tulkens P.M. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 2004, 64:913-936.
6. Belley A., Harris R., Beveridge T., Parr T.R., Moeck G. Differential targeting of cell wall assembly systems by oritavancin. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 17-20 September 2007, Chicago, IL 2007, ASM Press, Washington, DC, [Abstract C1-1472].
7. Biavasco F., Vignaroli C., Lupidi R., Manso E., Facinelli B., Varaldo P.E. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother 1997, 41:2165-2172.
8. Coyle E.A., Rybak M.J. Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2001, 45:706-709.
9. McKay G.A., Beaulieu S., Arhin F.F., Belley A., Sarmiento I., Parr T., et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2009, 63:1191-1199.
10. Arhin F.F., Draghi D.C., Pillar C.M., Parr T.R., Moeck G., Sahm D.F. Comparative in vitro activity profile of oritavancin against recent Gram-positive clinical isolates. Antimicrob Agents Chemother 2009, 53:4762-4771.
11. Badal R., Bouchillon S., Hoban D., Hawser S., Johnson A., Hackel M., et al. A multicenter evaluation of in vitro activity of oritavancin and comparators against staphylococci, enterococci and streptococci-the Orion study. 19th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), 16-19 May 2009, Helsinki, Finland 2009, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract P1618].
12. Draghi D.C., Pillar C., Moeck G., Arhin F.F., Sahm D. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008. 19th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), 16-19 May 2009, Helsinki, Finland 2009, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract P1620].
13. Arhin F.F., Kurepina N., Sarmiento I., Parr T.R., Moeck G., Kreiswirth B. Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates. Int J Antimicrob Agents 2010, 35:93-94.
14. Arhin F.F., Sarmiento I., Parr T.R., Moeck G. Activity of oritavancin against Staphylococcus aureus isolates that show heterogeneous resistance to vancomycin. 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 19-22 April 2008, Barcelona, Spain 2008, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract P-584].
15. Arhin F.F., Sarmiento I., Parr T.R., Moeck G. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. J Antimicrob Chemother 2009, 64:868-870.
16. Nguyen H.A., Denis O., Vergison A., Tulkens P.M., Struelens M., Van Bambeke F. Intracellular activity of antibiotics against a stable small colony variant (SCV) isolated from a CF patient in model Calu-3 human airway epithelial cells. 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 19-22 April 2008, Barcelona, Spain 2008, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract P1058].
17. Jones R.N., Barrett M.S., Erwin M.E. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob Agents Chemother 1997, 41:488-493.
18. US Food and Drug Administration. Oritavancin for the treatment of complicated skin and skin structure infections. FDA Briefing document for Anti-Infective Drugs Advisory Committee Meeting November 19, 2008. [accessed 5 February 2010]. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4394b2-03-FDA.pdf.
19. Mercier R.C., Houlihan H.H., Rybak M.J. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob Agents Chemother 1997, 41:1307-1312.
20. Belley A., Neesham-Grenon E., Arhin F.F., McKay G.A., Parr T.R., Moeck G. Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 2008, 52:3820-3822.
21. Lefort A., Saleh-Mghir A., Garry L., Carbon C., Fantin B. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob Agents Chemother 2000, 44:3017-3021.
22. Baltch A.L., Smith R.P., Ritz W.J., Bopp L.H. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1998, 42:2564-2568.
23. Mercier R.C., Stumpo C., Rybak M.J. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. J Antimicrob Chemother 2002, 50:19-24.
24. Belley A., Neesham-Grenon E., McKay G., Arhin F.F., Harris R., Beveridge T., et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother 2009, 53:918-925.
25. Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr Opin Pharmacol 2004, 4:471-478.
26. Arthur M., Depardieu F., Reynolds P., Courvalin P. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob Agents Chemother 1999, 43:1875-1880.
27. Linden P.K. Vancomycin resistance: are there better glycopeptides comingž. Expert Rev Anti Infect Ther 2008, 6:917-928.
28. Chien J., Allerheiligen S., Phillips D., Cerimele B., Thomasson H.R. Safety and pharmacokinetics of single intravenous doses of LY333328 diphosphate (glycopeptide) in healthy men. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 24-27 September 1998, San Francisco, CA 1998, ASM Press, Washington, DC, [Abstract A-55].
29. Fetterly G.J., Ong C.M., Bhavnani S.M., Loutit J.S., Porter S.B., Morello L.G., et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother 2005, 49:148-152.
30. Targanta Therapeutics Corporation. NUVOCID® (oritavancin diphosphate for injection) for treatment of complicated skin and skin structure infections. NDA 22-153. Briefing document for the Anti-Infective Drugs Advisory Committee November 19, 2008. [accessed 5 February 2010]. http://www.fda.gov/ohrms/DOCKETS/ac/08/briefing/2008-4394b2-04-Targanta.pdf.
31. 14C-oritavancin. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 16-19 December 2001, Chicago, IL 2001, ASM Press, Washington, DC, [Abstract A-2193].
32. Bhavnani S.M., Owen J.S., Loutit J.S., Porter S.B., Ambrose P.G. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis 2004, 50:95-102.
33. Rodvold K.A., Gotfired M.H., Loutit J.S., Porter S.B. Plasma and intrapulmonary concentrations of oritavancin and vancomycin in normal healthy adults. 14th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 1-4 May 2004, Prague, Czech Republic 2004, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract O254].
34. Belanger O., Rozborskaya O., Dietrich E., Malouin M., Ostiguy V., Fadhil I., et al. Quantitative determination and pharmacokinetics of oritavancin in rabbit serum and tibia. 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 19-22 April 2008, Barcelona, Spain 2008, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract P-1061].
35. Xiong Y.Q., Li Y., Abdel Hady W., Lehoux D., Bélanger O., Moeck G., et al. Efficacy of oritavancin (ORI), a lipoglycopeptide antibiotic, in a rat Staphylococcus aureus endocarditis (IE) model: microbiological and bioluminescent assessments. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008, Washington, DC 2008, ASM Press, Washington, DC, [Abstract B-1011].
36. Kaatz G.W., Seo S.M., Aeschlimann J.R., Houlihan H.H., Mercier R.C., Rybak M.J. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1998, 42:981-983.
37. Saleh-Mghir A., Lefort A., Petegnief Y., Dautrey S., Vallois J.M., Le Guludec D., et al. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1999, 43:115-120.
38. Gerber J., Smirnov A., Wellmer A., Ragheb J., Prange J., Schutz E., et al. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother 2001, 45:2169-2172.
39. Bhavnani S., Rubino C., Forrest A., Lehoux D., Okusanya O.O., Drusano G.L., et al. Use of pharmacokinetic-pharmacodynamic (PK-PD) principles to guide clinical drug development for oritavancin (ORI). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 17-20 September 2007, Chicago, IL 2007, ASM Press, Washington, DC, [Abstract A-51].
40. Bouza E. New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2009, 15(Suppl 7):44-52.
41. Van Bambeke F., Carryn S., Snoeck A., Mingeot-Leclercq M., Tulkens P.M. LY333328 (oritavancin) glycopeptide accumulates in cultured macrophages but is only bacteriostatic towards intracellular Listeria monocytogenes. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 16-19 December 2001, Chicago, IL 2001, ASM Press, Washington, DC, [Abstract A-2069].
42. Van Bambeke F., Carryn S., Seral C., Chanteux H., Tyteca D., Mingeot-Leclercq M.P., et al. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother 2004, 48:2853-2860.
43. Fetterly G., Owen J., Bhavnani S., Ambrose P., Morello L., Porter S., et al. Effect of hepatic impairment on the pharmacokinetics of the novel glycopeptide oritavancin. The American Association of Pharmaceutical Scientists Annual Meeting Abstracts, 7-10 November 2004, Baltimore, MD 2004, The American Association of Pharmaceutical Scientists, Arlington, VA, [Abstract T3313].
44. Hartman C.S., Wasilewski M.M., Moriarty S.R., Bates B.M. Hepatic insufficiency and outcomes in patients with complicated skin and skin-structure infections treated with oritavancin. 19th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), 16-19 May 2009, Helsinki, Finland 2009, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract P-1852].
45. Owen J.S., Bhavnani S.M., Fielder-Kelly J., Loutit J.S., Porter S.B. Population pharmacokinetics of oritavancin. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 30 October-2 November 2004, Washington, DC 2004, ASM Press, Washington, DC, [Abstract A-20].
46. Mann H.J., Kumar A., Keshtgarpour M., Flynn M.A., Deng H., Rafai Far A., et al. Oritavancin is not cleared in vitro by low flux, high flux or continuous renal replacement therapy (CRRT) dialyzers. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12-15 September 2009, San Francisco, CA 2009, ASM Press, Washington, DC, [Abstract A1-1290].
47. Zelenitsky S.A., Karlowsky J.A., Zhanel G.G., Hoban D.J., Nicas T. Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains. Antimicrob Agents Chemother 1997, 41:1407-1408.
48. McKay G.A., Beaulieu S., Belley A., Arhin F.F., Parr T.R., Moeck G. In vitro time kill studies of oritavancin against drug resistant isolates of Staphylococcus aureus and enterococci. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 17-20 September 2007, Chicago, IL 2007, ASM Press, Washington, DC, [Abstract E-1614].
49. Boylan C.J., Campanale K., Iversen P.W., Phillips D.L., Zeckel M.L., Parr T.R. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2003, 47:1700-1706.
50. Sahm D.F., Moeck G., Arhin F.F., Draghi D. In vitro activity profile of oritavancin against resistant staphylococcal populations from a recent surveillance initiative. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 17-20 September 2007, Chicago, IL 2007, ASM Press, Washington, DC, [Abstract E-1617].
51. Dunbar L.M., Milata J., Fitzpatrick M., Larrison A., McClure T., Wasilewski M.M. Efficacy of oritavancin at single or infrequent doses for the treatment of complicated skin and skin-structure infections. 19th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), 16-19 May 2009, Helsinki, Finland 2009, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract P-1849].
52. Rupp M.E., Fey P.D., Longo G.M. Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model. J Antimicrob Chemother 2001, 47:705-707.
53. Cabellos C., Fernandez A., Maiques J.M., Tubau F., Ardanuy C., Viladrich P.F., et al. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 2003, 47:1907-1911.
54. Lehoux D., Fadhil I., Gagné J., Bédard I., Ostiguy V., Malouin M., et al. Efficacy of oritavancin against Clostridium difficile (CD) infection in the hamster model of CD infection (CDI). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008, Washington, DC 2008, ASM Press, Washington, DC, [Abstract B-067].
55. Baines S.D., O'Connor R., Saxton K., Freeman J., Wilcox M.H. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008, 62:1078-1085.
56. Wasilewski M.M., Disch D.P., McGill J.M., Harris H.W., O'Riordan W.D., Zeckel M.L. Equivalence of shorter course therapy with oritavancin vs. vancomycin/cephalexin in complicated skin/skin structure infections. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 16-19 December 2001, Chicago, IL 2001, ASM Press, Washington, DC, [Abstract UL-18].
57. Giamarellou H., O'Riordan W.D., Harris H., Owen S., Porter S., Loutit J.S. Phase III trial comparing 3-7 days of oritavancin vs. 10-14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (CSSI). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14-17 September 2003, Chicago, IL 2003, ASM Press, Washington, DC, [Abstract L-739a].
58. Hartman C.S., Wasilewski M.M., Moriarty S.R., Bates B.M. Oritavancin in the treatment of immunocompromised patients with complicated skin and skin-structure infections. 19th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), 16-19 May 2009, Helsinki, Finland 2009, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract P-1850].
59. Hartman C.S., Wasilewski M.M., Moriarty S.R., Bates B.M. Oritavancin in the treatment of diabetic patients with complicated skin and skin-structure infections. 19th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), 16-19 May 2009, Helsinki, Finland 2009, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract P-1851].
60. De la Pena A., Chien J., Geiser J., Brown T., Farlow D., Weerakkody G., et al. Microbiological outcomes and pharmacokinetics of oritavancin in patients with Gram-positive bacteremia. 12th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 21-24 April 2002, Milan, Italy 2002, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract P1091].
61. Loutit J., O'Riordan W., San Juan J., Mensa J., Hanning R., Huang S., et al. Phase 2 trial comparing four regimens of oritavancin vs. comparator in the treatment of patients with S. aureus bacteremia. 14th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 1-4 May 2004, Prague, Czech Republic 2004, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract P541].
62. Rubino C.M., Van Wart S.A., Bhavnani S.M., Ambrose P.G., McCollam J.S., Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother 2009, 53:4422-4428.
63. Rubino C.M., Bhavnani S.M., Forrest A., Okusanya O.O., Lehoux D., Drusano G.L., et al. Use of pharmacokinetic-pharmacodynamic principles for decision support for short-course oritavancin dosing regimens for complicated skin and skin structure infections. 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 19-22 April 2008, Barcelona, Spain 2008, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract O-152].
64. Lehoux D., Laquerre K., Ostiguy V., Fadhil I., Malouin M., Cadieux C., et al. Comparative efficacy of oritavancin (ORI) against methicillin-sensitive and -resistant Staphylococcus aureus strains in a neutropenic-mouse thigh infection model. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12-15 September 2009, San Francisco, CA 2009, ASM Press, Washington, DC, [Abstract B-1324].
65. Moriarty S.R., Wasilewski M.M., Rosen A.S., Perry M. Incidence of histamine-like infusion reactions in 2 Phase III studies comparing oritavancin and vancomycin in the treatment of complicated skin and skin structure infections. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008, Washington, DC 2008, ASM Press, Washington, DC, [Abstract L-1515].
66. Moriarty S.R., Wasilewski M.M., Rosen A.S., Perry M. Safety of oritavancin versus vancomycin for treatment of patients with complicated skin and skin-structure infections. 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 16-19 May 2009, Helsinki, Finland 2009, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland, [Abstract P-1853].
67. Guskey M.T., Tsuji B.T. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy 2010, 30:80-94.
68. Friedman H.L., Moriarty S.R., Hund M.E., Lee S.K., Mason J.W., Moon T.E., et al. A Phase I, double-blind, randomized, placebo- and positive-controlled, single dose, parallel design trial to assess the potential electrocardiographic effects of oritavancin in healthy adults. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008, Washington, DC 2008, ASM Press, Washington, DC, [Abstract A-1893].
69. Van Bambeke F., Saffran J., Mingeot-Leclercq M.P., Tulkens P.M. Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob Agents Chemother 2005, 49:1695-1700.
70. Barton E., MacGowan A. Future treatment options for Gram-positive infections-looking ahead. Clin Microbiol Infect 2009, 15(Suppl 6):17-25.
71. Tenover F.C., Biddle J.W., Lancaster M.V. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001, 7:327-332.
72. Appelbaum P.C. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007, 30:398-408.